Press release MHRA approves GLP –one receptor agonist semaglutide to scale back possibility of significant coronary heart challenges in obese or overweight Older people Semaglutide is the primary weight reduction drug approved in britain like a preventative cure for all those with recognized cardiovascular diseaseBeneath existing Wonderful pointe